PRTX-100: Pre-clinical Studies Demonstrate Efficacy against RA in Gold-Standard Model

[Guest guest]

PRTX-100 Demonstrates Efficacy against Rheumatoid Arthritis in Gold-Standard

Model

Protalex Presents Data at Fifth International Conference on Autoimmune

Disorders

http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view & ne\

wsId=20061130005230 & newsLang=en

Protalex, Inc. announced that data from pre-clinical studies of its PRTX-100

compound in development for the treatment of autoimmune and inflammatory

diseases, demonstrated efficacy in well-established murine (mouse) models of

rheumatoid arthritis. The data from the pre-clincial studies were presented

by Joe J. Dervan, Ph.D., Director of Protein Chemistry and Biopharmaceutical

Manufacturing at Protalex, at the Fifth International Conference on

Autoimmune Disorders in Sorrento, Italy.

The pre-clincial studies involved administering PRTX-100 into

collagen-induced arthritis (CIA) murine models, which mirror many of the

disease symptoms of rheumatoid arthritis, including polyarthritis, synovitis

and caritage/bone erosions. In the studies, reduction in clinical scores and

pathology with PRTX-100 were equivalent to the suppression seen in mice

treated with etanercept (Enbrel), an FDA-approved treatment for rheumatoid

arthritis. Furthermore, PRTX-100 was able to delay onset and decrease

severity of symptoms.

" We are encouraged by the results of the study, particularly because

PRTX-100 demonstrated efficacy in the gold-standard model for evaluating

rheumatoid arthritis therapies, " said H. Kane, President and Chief

Executive Officer of Protalex. " The study reinforces our belief in the

potential of PRTX-100. "

About PRTX-100

PRTX-100 is a highly-purified form of Staphylococcal Protein A. PRTX-100

binds directly to monocytes and a subset of B-cells that are involved in the

development and progression of various autoimmune diseases, enabling the

compound to modulate the function of these cells and restore the balance of

the immune system.

About Protalex, Inc.

Protalex, Inc. is a biotechnology company engaged in the development of a

new class of drugs for the treatment of Rheumatoid Arthritis (RA),

Idiopathic Thrombocytopenic Purpura (ITP) and a host of other autoimmune

disorders. Additional information about Protalex, Inc. can be found at

www.protalex.com.

Cautionary Statement Regarding Forward Looking Information

This release contains forward-looking information about Protalex, Inc. that

are intended to be covered by the safe harbor for forward-looking statements

provided by the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are statements that are not historical facts.

These statements can be identified by the use of forward-looking terminology

such as " believe, " " expect, " " may, " " will, " " should, " " project, " " plan, "

" seek, " " intend, " or " anticipate " or the negative thereof or comparable

terminology, and include discussions of strategy, and statements about

industry trends and Protalex's future performance, operations and products.

This forward-looking information should be considered only in connection

with " Risk Factors " in Protalex's Annual Report on Form 10-KSB filed with

the Securities and Exchange Commission ( " SEC " ) on July 28, 2006 and its

other periodic reports filed with the SEC. Protalex assumes no obligation to

update any forward-looking statements or information set forth in this press

release.